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Abstract
There has in recent years been great concern about possible cardiac side effects of
thiazolidinediones (TZDs). We present a case-report of a 60 year-old male who developed
significant mitral regurgitation during six months treatment with pioglitazone in parallel with
laboratory indications of fluid retention. Echocardiography six months after discontinuation of
medication showed regression of mitral regurgitation and the laboratory parameters were also
normalized. It is noteworthy that six months treatment with pioglitazone could induce significant
valve dysfunction, which was reversible, and this underlines the importance of carefully monitoring
patients when placing them on treatment with TZDs.
Introduction
There is an ongoing discussion concerning the possible
effects of thiazolidinediones (TZDs) on the heart. In a
recent meta/teleo-analysis Singh et al concluded that heart
failure might occur at both high and low doses, usually
weeks to months after initiating TZDs and in patients
without a history of heart failure [1].
Case presentation
The patient is a sixty-year-old man with type 2 diabetes
known since 15 years. He has proliferative retinopathy
and microalbuminuria, no history or clinical signs of car-
diovascular disease, stopped smoking 30 years ago. Fail-
ure to achieve optimal glycaemic control on treatment
with 850 mg metformin/day (reduced dose because of
elevated creatinine) and glimepiride 6 mg/day was evi-
dent with HbA1c >10%. The patient entered an ongoing
study. He received add-on treatment with pioglitazone 30
mg/day that was increased after 16 weeks to 45 mg/day
since HbA1c was 8.3% and no side effects were recorded.
Standard transthoracic echocardiography examinations
were performed with Sonos 5500 (Philips Medical, Best,
the Netherlands) at baseline (15/12 2006), after six
months pioglitazone therapy (25/6 2007), and six
months after discontinuation of pioglitazone (20/12
2007). Cardiac size and volumes were quantified accord-
ing to current guidelines [2] and echocardiography esti-
mate of left ventricular filling pressure were calculated as
previously described [3]. Valvular regurgitation was
graded visually (0.5/1/2/3-trivial, mild, moderate, and
severe) [4]. Brain BNP and haemoglobin were also meas-
ured at start and after six months treatment. After 26
weeks of treatment the HbA1c decreased to 7.4% in paral-
lel with a decrease in haemoglobin from 113 at start to
100 g/l, a weight gain of 3 kg and an increase in brain BNP
from 5 to 22 pmol/l. The patient did not show any clinical
signs or symptoms of cardiopulmonary affection or
peripheral oedema. Echocardiography examination at
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baseline and at the two subsequent examinations showed
a mitral valve with normal morphology, no prolaps or
thickened leaflets could be observed. The baseline
echocardiography examination showed trivial mitral
regurgitation, whereas the echocardiography examination
after six months of pioglitazone therapy showed newly
developed moderate mitral regurgitation, with a predom-
inantly central jet. Furthermore, ejection fraction was
increased and left ventricular- and atrial dimensions were
also increased, compared to baseline values. In addition,
estimate of left ventricular filling pressure (E/Em) was
slightly increased. All the echocardiography alterations
and laboratory indications of fluid retention (BNP and
haemoglobin) were back to baseline values six months
after discontinuation of pioglitazone therapy. Figure 1, 2,
3 display echocardiography images from apical 4-cham-
ber view at baseline, after six month pioglitazone therapy
and six months after discontinuation of pioglitazone ther-
apy, respectively. Summary of anthropometrical, echocar-
diography and laboratory data are displayed in Table 1.
Discussion
This case-report highlights the importance of careful mon-
itoring of patients under treatment with TZDs. In this
case, changes in haemoglobin and BNP indicated fluid
retention in the absence of clinical signs or symptoms of
cardiopulmonary stress or oedema. What caused the
mitral regurgitation? One plausible hypothesis is that the
fluid retention caused left ventricular dilatation which in
turn resulted in mitral annular dilatation and to altered
papillary muscle orientation, which then leads to inade-
quate mitral leaflet coaptation. Mitral regurgitations that
are caused by left ventricular dilatation tend to have a cen-
tral jet, as in our patient. It is, however, possible that there
was some structural weakness in the mitral valve appara-
tus that was not detected on the transthoracic echocardi-
ography examinations and that this could in part be
contributing to the regurgitation. There is a need for tools
to help clinicians to identify subsets of patients for whom
this kind of therapy is likely to have particularly favoura-
ble/unfavourable effect, using readily identifiable clinical
and laboratory factors. BNP, being a peptide hormone
released from the cardiac ventricles in response to myo-
cyte stretch have generated a lot of attention in recent
years and have been proposed as potential diagnostic and
prognostic marker for cardiac disease but currently there
are no clear algorithms on how this should be imple-
mented into clinical practice. However, the knowledge is
increasing in this field and hopefully the results will ena-
ble clinicians to select proper therapy for individual
patients in future.
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Display of end-systolic image from apical 4-chamber view  after six month of treatment with pioglitazone. The white,  thicker, arrow indicates the newly developed moderate  mitral regurgitation.   Figure 2
Display of end-systolic image from apical 4-chamber 
view after six month of treatment with pioglitazone. 
The white, thicker, arrow indicates the newly developed 
moderate mitral regurgitation.  
Display of end-systolic image from apical 4-chamber view  before treatment with pioglitazone Figure 1
Display of end-systolic image from apical 4-chamber view 
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Table 1: Descriptive statistics of anthropometrical, 
echocardiography and laboratory data.
Date 15/12 2006 25/62007 20/12 2007
Weight (kg) 82.5 85.7 85.7
HbA1c (%) 10 7.4 7.7
BNP (pmol/l) 5 22 8
Haemoglobin (g/l) 113 100 116
LVDD (mm) 42 49 41
LVSD (mm) 22 24 22
IVS (mm) 10 10 10
Post (mm) 9 9 9
LA (mm) 35 41 35
LV diastolic vol (ml) 100 131 104
LV systolic vol (ml) 34 35 33
EF (%) 66 73 68
LA vol (ml) 53 68 54
E/A 0.7 0.9 0.7
E/Em 10 12 10
Mitral regurgitation (1–3) 0.5 2 1
Display of end-systolic image from apical 4-chamber  view six months after discontinuation of pioglitazone.  The yellow, thinner, arrow indicates the remaining mild  mitral regurgitation. Figure 3
Display of end-systolic image from apical 4-chamber view six 
months after discontinuation of pioglitazone. The yellow, 
thinner, arrow indicates the remaining mild mitral regurgita-
tion.